Strong H1 results saw contribuons from marketed products Cresemba and Zevtera grow 17% YoY to CHF62.0m with management confirming 2020E revenue guidance between CHF128m - CHF138m. We highlight the connued growth of cash generang, non deferred revenuesfrom these products(CHF36.5m,+21% YoY), which more closely reflect the underlying in market performance and are increasingly responsible for greater proporon of total revenue. We maintain and reiterate our OUTPERFORM recommendaon, as the current share price does not reflect the full potenal of both marketed and clinical-stage pipeline assets, in our view.